ERIC DOBMEIER Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for ERIC DOBMEIER.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of ERIC DOBMEIER. ERIC DOBMEIER is Chief Business Officer in SEATTLE GENETICS INC /WA ($SGEN) and Chief Operating Officer in SEATTLE GENETICS INC /WA ($SGEN) and Sr. VP, Corporate Development in SEATTLE GENETICS INC /WA ($SGEN) and V. P., Corporate Affairs in SEATTLE GENETICS INC /WA ($SGEN) and Vice President, in SEATTLE GENETICS INC /WA ($SGEN) and Director in STEMLINE THERAPEUTICS INC ($STML) and President, CEO in ADURO BIOTECH, INC. ($ADRO) and Director in Adaptive Biotechnologies Corp ($ADPT) and Director in Versartis, Inc. ($VSAR) and Director in Atara Biotherapeutics, Inc. ($ATRA).
Latest Insider Trading Transactions of ERIC DOBMEIER
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ADPT, ARAV, ATRA, ADRO, SGEN, STML
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15 2021 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Option Exercise | M | 0.35 | 20,000 | 7,000 | 423,358 | |
| Jun 15 2021 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Buy | M | 0.35 | 20,000 | 7,000 | 97,837 | 77.8 K to 97.8 K (+25.69 %) |
| Feb 17 2021 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Option Exercise | A | 66.50 | 3,759 | 249,974 | 3,759 | |
| Feb 17 2021 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Grant | A | 0.00 | 1,504 | 0 | 1,504 | 0 to 1.5 K |
| Feb 12 2021 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Option Exercise | A | 0.00 | 60,743 | 0 | 60,743 | |
| Feb 12 2021 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Option Exercise | A | 15.14 | 178,600 | 2,704,004 | 178,600 | |
| Jan 06 2021 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Option Exercise | M | 6.32 | 10,000 | 63,200 | 35,000 | |
| Jan 06 2021 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 59.46 | 400 | 23,784 | 0 | 400 to 0 (-100.00 %) |
| Jan 06 2021 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 58.67 | 592 | 34,733 | 400 | 992 to 400 (-59.68 %) |
| Jan 06 2021 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 57.76 | 5,725 | 330,676 | 992 | 6.7 K to 992 (-85.23 %) |
| Jan 06 2021 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 56.10 | 3,283 | 184,176 | 6,717 | 10 K to 6.7 K (-32.83 %) |
| Jan 06 2021 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Buy | M | 6.32 | 10,000 | 63,200 | 10,000 | 0 to 10 K |
| Dec 22 2020 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Option Exercise | M | 0.35 | 20,000 | 7,000 | 443,358 | |
| Dec 22 2020 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Buy | M | 0.35 | 20,000 | 7,000 | 76,837 | 56.8 K to 76.8 K (+35.19 %) |
| Dec 10 2020 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Buy | P | 13.08 | 2,000 | 26,150 | 56,837 | 54.8 K to 56.8 K (+3.65 %) |
| Dec 10 2020 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Buy | P | 13.24 | 2,000 | 26,483 | 54,837 | 52.8 K to 54.8 K (+3.79 %) |
| Nov 23 2020 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Buy | P | 13.67 | 929 | 12,699 | 52,837 | 51.9 K to 52.8 K (+1.79 %) |
| Nov 23 2020 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Buy | P | 13.69 | 571 | 7,817 | 51,908 | 51.3 K to 51.9 K (+1.11 %) |
| Nov 23 2020 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Buy | P | 13.50 | 500 | 6,750 | 51,337 | 50.8 K to 51.3 K (+0.98 %) |
| Nov 13 2020 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Buy | P | 13.75 | 2,500 | 34,375 | 50,837 | 48.3 K to 50.8 K (+5.17 %) |
| Nov 13 2020 | ADRO | CHINOOK THERAPEUTI ... | DOBMEIER ERIC | President, CEO | Buy | P | 13.86 | 2,000 | 27,720 | 48,337 | 46.3 K to 48.3 K (+4.32 %) |
| Oct 07 2020 | ADRO | ADURO BIOTECH, INC ... | DOBMEIER ERIC | President, CEO | Option Exercise | A | 0.00 | 92,389 | 0 | 92,389 | |
| Oct 07 2020 | ADRO | ADURO BIOTECH, INC ... | DOBMEIER ERIC | President, CEO | Option Exercise | A | 0.00 | 92,389 | 0 | 92,389 | |
| Oct 07 2020 | ADRO | ADURO BIOTECH, INC ... | DOBMEIER ERIC | President, CEO | Option Exercise | A | 14.77 | 271,647 | 4,012,226 | 271,647 | |
| Oct 07 2020 | ADRO | ADURO BIOTECH, INC ... | DOBMEIER ERIC | President, CEO | Option Exercise | A | 14.77 | 271,647 | 4,012,226 | 271,647 | |
| Oct 07 2020 | ADRO | ADURO BIOTECH, INC ... | DOBMEIER ERIC | President, CEO | Option Exercise | A | 0.42 | 423,555 | 177,893 | 423,555 | |
| Oct 07 2020 | ADRO | ADURO BIOTECH, INC ... | DOBMEIER ERIC | President, CEO | Option Exercise | A | 0.42 | 423,555 | 177,893 | 423,555 | |
| Oct 07 2020 | ADRO | ADURO BIOTECH, INC ... | DOBMEIER ERIC | President, CEO | Option Exercise | A | 0.35 | 463,358 | 162,175 | 463,358 | |
| Oct 07 2020 | ADRO | ADURO BIOTECH, INC ... | DOBMEIER ERIC | President, CEO | Option Exercise | A | 0.35 | 463,358 | 162,175 | 463,358 | |
| Oct 07 2020 | ADRO | ADURO BIOTECH, INC ... | DOBMEIER ERIC | President, CEO | Grant | A | 0.00 | 46,337 | 0 | 46,337 | 0 to 46.3 K |
| Oct 07 2020 | ADRO | ADURO BIOTECH, INC ... | DOBMEIER ERIC | President, CEO | Grant | A | 0.00 | 46,337 | 0 | 46,337 | 0 to 46.3 K |
| Oct 02 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Option Exercise | M | 6.32 | 10,000 | 63,200 | 45,000 | |
| Oct 02 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 49.21 | 776 | 38,187 | 0 | 776 to 0 (-100.00 %) |
| Oct 02 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 48.47 | 9,224 | 447,087 | 776 | 10 K to 776 (-92.24 %) |
| Oct 02 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Buy | M | 6.32 | 10,000 | 63,200 | 10,000 | 0 to 10 K |
| Jul 08 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Option Exercise | M | 6.32 | 10,000 | 63,200 | 55,000 | |
| Jul 08 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 47.98 | 400 | 19,192 | 0 | 400 to 0 (-100.00 %) |
| Jul 08 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 47.34 | 9,600 | 454,464 | 400 | 10 K to 400 (-96.00 %) |
| Jul 08 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Buy | M | 6.32 | 10,000 | 63,200 | 10,000 | 0 to 10 K |
| Jun 17 2020 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Option Exercise | A | 10.54 | 24,500 | 258,230 | 24,500 | |
| Jun 17 2020 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Grant | A | 0.00 | 8,000 | 0 | 28,000 | 20 K to 28 K (+40.00 %) |
| Jun 05 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Option Exercise | M | 6.32 | 5,000 | 31,600 | 65,000 | |
| Jun 05 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 39.79 | 5,000 | 198,950 | 0 | 5 K to 0 (-100.00 %) |
| Jun 05 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Buy | M | 6.32 | 5,000 | 31,600 | 5,000 | 0 to 5 K |
| May 21 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Option Exercise | M | 6.32 | 5,000 | 31,600 | 70,000 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 40.00 | 5,000 | 200,000 | 0 | 5 K to 0 (-100.00 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Buy | M | 6.32 | 5,000 | 31,600 | 5,000 | 0 to 5 K |
| May 21 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Option Exercise | M | 6.32 | 5,000 | 31,600 | 70,000 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 40.00 | 5,000 | 200,000 | 0 | 5 K to 0 (-100.00 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Buy | M | 6.32 | 5,000 | 31,600 | 5,000 | 0 to 5 K |
| May 08 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Option Exercise | M | 6.32 | 5,000 | 31,600 | 75,000 | |
| May 08 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 35.00 | 5,000 | 175,000 | 0 | 5 K to 0 (-100.00 %) |
| May 08 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Buy | M | 6.32 | 5,000 | 31,600 | 5,000 | 0 to 5 K |
| Feb 18 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Option Exercise | A | 31.71 | 8,888 | 281,838 | 8,888 | |
| Dec 30 2019 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Option Exercise | M | 6.32 | 15,000 | 94,800 | 85,000 | |
| Dec 30 2019 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | D | 29.91 | 2 | 60 | 0 | 2 to 0 (-100.00 %) |
| Dec 30 2019 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | D | 29.29 | 14,998 | 439,291 | 2 | 15 K to 2 (-99.99 %) |
| Dec 30 2019 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Buy | M | 6.32 | 15,000 | 94,800 | 15,000 | 0 to 15 K |
| Jul 01 2019 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Option Exercise | A | 20.25 | 13,000 | 263,250 | 13,000 | |
| Jul 01 2019 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Grant | A | 0.00 | 4,000 | 0 | 20,000 | 16 K to 20 K (+25.00 %) |
| Jul 01 2019 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Buy | P | 19.50 | 2,000 | 39,000 | 16,000 | 14 K to 16 K (+14.29 %) |
| Jun 18 2018 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Option Exercise | A | 45.65 | 5,000 | 228,250 | 5,000 | |
| Jun 18 2018 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Grant | A | 0.00 | 1,500 | 0 | 14,000 | 12.5 K to 14 K (+12.00 %) |
| Dec 22 2017 | VSAR | Versartis, Inc. | DOBMEIER ERIC | Director | Grant | A | 0.00 | 11,200 | 0 | 18,160 | 7 K to 18.2 K (+160.92 %) |
| Dec 06 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 26.10 | 3,729 | 97,327 | 24,700 | |
| Dec 06 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 41.04 | 2,436 | 99,973 | 0 | |
| Dec 06 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 41.04 | 2,436 | 99,973 | 119,860 | 117.4 K to 119.9 K (+2.07 %) |
| Dec 06 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 58.75 | 3,729 | 219,092 | 117,424 | 121.2 K to 117.4 K (-3.08 %) |
| Dec 06 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 26.10 | 3,729 | 97,327 | 121,153 | 117.4 K to 121.2 K (+3.18 %) |
| Nov 17 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 26.10 | 10,000 | 261,000 | 28,429 | |
| Nov 17 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 26.10 | 6,911 | 180,377 | 38,429 | |
| Nov 17 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 15.46 | 8,489 | 131,240 | 0 | |
| Nov 17 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 15.46 | 9,600 | 148,416 | 8,489 | |
| Nov 17 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 59.13 | 10,000 | 591,250 | 117,424 | 127.4 K to 117.4 K (-7.85 %) |
| Nov 17 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 26.10 | 10,000 | 261,000 | 127,424 | 117.4 K to 127.4 K (+8.52 %) |
| Nov 17 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 57.95 | 8,489 | 491,938 | 117,424 | 125.9 K to 117.4 K (-6.74 %) |
| Nov 17 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 15.46 | 8,489 | 131,240 | 125,913 | 117.4 K to 125.9 K (+7.23 %) |
| Nov 17 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 57.98 | 6,911 | 400,700 | 117,424 | 124.3 K to 117.4 K (-5.56 %) |
| Nov 17 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 26.10 | 6,911 | 180,377 | 124,335 | 117.4 K to 124.3 K (+5.89 %) |
| Nov 17 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 57.80 | 9,600 | 554,837 | 117,424 | 127 K to 117.4 K (-7.56 %) |
| Nov 17 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 15.46 | 9,600 | 148,416 | 127,024 | 117.4 K to 127 K (+8.18 %) |
| Sep 05 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 15.46 | 25,000 | 386,500 | 18,089 | |
| Sep 05 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 52.24 | 25,000 | 1,305,893 | 117,424 | 142.4 K to 117.4 K (-17.55 %) |
| Sep 05 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 15.46 | 25,000 | 386,500 | 142,424 | 117.4 K to 142.4 K (+21.29 %) |
| Aug 30 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 47.89 | 5,343 | 255,900 | 117,424 | 122.8 K to 117.4 K (-4.35 %) |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | A | 46.37 | 85,344 | 3,957,401 | 85,344 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | A | 46.37 | 2,156 | 99,974 | 2,156 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Grant | A | 0.00 | 35,000 | 0 | 122,767 | 87.8 K to 122.8 K (+39.88 %) |
| Jun 20 2017 | STML | STEMLINE THERAPEUT ... | DOBMEIER ERIC | Director | Option Exercise | A | 8.20 | 24,000 | 196,800 | 24,000 | |
| Jun 20 2017 | STML | STEMLINE THERAPEUT ... | DOBMEIER ERIC | Director | Grant | A | 0.00 | 10,000 | 0 | 27,963 | 18 K to 28 K (+55.67 %) |
| Jun 12 2017 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Option Exercise | A | 13.20 | 21,500 | 283,800 | 21,500 | |
| Jun 12 2017 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Grant | A | 0.00 | 5,000 | 0 | 12,500 | 7.5 K to 12.5 K (+66.67 %) |
| Jun 06 2017 | VSAR | Versartis, Inc. | DOBMEIER ERIC | Director | Option Exercise | A | 15.83 | 6,850 | 108,401 | 6,850 | |
| Jun 06 2017 | VSAR | Versartis, Inc. | DOBMEIER ERIC | Director | Option Exercise | A | 15.83 | 6,850 | 108,401 | 6,850 | |
| Jun 06 2017 | VSAR | Versartis, Inc. | DOBMEIER ERIC | Director | Grant | A | 0.00 | 3,480 | 0 | 6,960 | 3.5 K to 7 K (+100.00 %) |
| Jun 06 2017 | VSAR | Versartis, Inc. | DOBMEIER ERIC | Director | Grant | A | 0.00 | 3,480 | 0 | 3,480 | 0 to 3.5 K |
| Jan 05 2017 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Option Exercise | A | 15.08 | 5,500 | 82,940 | 5,500 | |
| Jan 05 2017 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Grant | A | 0.00 | 2,000 | 0 | 7,500 | 5.5 K to 7.5 K (+36.36 %) |
| Dec 12 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 20.52 | 9,700 | 199,044 | 0 | |
| Dec 12 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 20.52 | 2,800 | 57,456 | 9,700 | |
| Dec 12 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 65.90 | 9,700 | 639,234 | 87,767 | 97.5 K to 87.8 K (-9.95 %) |
| Dec 12 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 20.52 | 9,700 | 199,044 | 97,467 | 87.8 K to 97.5 K (+11.05 %) |
| Dec 12 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 66.00 | 2,800 | 184,808 | 87,767 | 90.6 K to 87.8 K (-3.09 %) |
| Dec 12 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 20.52 | 2,800 | 57,456 | 90,567 | 87.8 K to 90.6 K (+3.19 %) |
| Sep 15 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 12.00 | 300 | 3,600 | 0 | |
| Sep 15 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 12.00 | 22,618 | 271,416 | 300 | |
| Sep 15 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 54.41 | 300 | 16,324 | 87,767 | 88.1 K to 87.8 K (-0.34 %) |
| Sep 15 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 12.00 | 300 | 3,600 | 88,067 | 87.8 K to 88.1 K (+0.34 %) |
| Sep 15 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 54.03 | 22,618 | 1,222,146 | 87,767 | 110.4 K to 87.8 K (-20.49 %) |
| Sep 15 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 12.00 | 22,618 | 271,416 | 110,385 | 87.8 K to 110.4 K (+25.77 %) |
| Aug 30 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | A | 45.30 | 70,293 | 3,184,273 | 70,293 | |
| Aug 30 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | A | 45.30 | 2,207 | 99,977 | 2,207 | |
| Aug 30 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Grant | A | 0.00 | 29,000 | 0 | 87,767 | 58.8 K to 87.8 K (+49.35 %) |
| Aug 24 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 26.10 | 3,831 | 99,989 | 0 | |
| Aug 24 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 48.00 | 12,589 | 604,272 | 58,767 | 71.4 K to 58.8 K (-17.64 %) |
| Aug 24 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 26.10 | 3,831 | 99,989 | 71,356 | 67.5 K to 71.4 K (+5.67 %) |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 46.59 | 5,411 | 252,102 | 67,525 | 72.9 K to 67.5 K (-7.42 %) |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | A | 39.15 | 44,946 | 1,759,636 | 44,946 | |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | A | 39.15 | 2,554 | 99,989 | 2,554 | |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 20.52 | 4,688 | 96,198 | 0 | |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 15.46 | 245 | 3,788 | 0 | |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Grant | A | 0.00 | 19,000 | 0 | 98,340 | 79.3 K to 98.3 K (+23.95 %) |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 15.46 | 245 | 3,788 | 79,340 | 79.1 K to 79.3 K (+0.31 %) |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 20.52 | 4,688 | 96,198 | 79,095 | 74.4 K to 79.1 K (+6.30 %) |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 42.02 | 8,548 | 359,226 | 74,407 | 83 K to 74.4 K (-10.30 %) |
| May 26 2016 | STML | STEMLINE THERAPEUT ... | DOBMEIER ERIC | Director | Option Exercise | A | 6.78 | 34,000 | 230,520 | 34,000 | |
| Mar 17 2016 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Buy | P | 13.86 | 3,000 | 41,565 | 5,500 | 2.5 K to 5.5 K (+120.00 %) |
| Jan 05 2016 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Option Exercise | A | 24.05 | 10,500 | 252,525 | 10,500 | |
| Dec 17 2015 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Buy | P | 22.00 | 2,500 | 55,000 | 2,500 | 0 to 2.5 K |
| Nov 06 2015 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 42.50 | 17,452 | 741,710 | 80,888 | 98.3 K to 80.9 K (-17.75 %) |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | A | 39.15 | 44,946 | 1,759,636 | 44,946 | |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | A | 39.15 | 2,554 | 99,989 | 2,554 | |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 20.52 | 4,688 | 96,198 | 0 | |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 15.46 | 245 | 3,788 | 0 | |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Grant | A | 0.00 | 19,000 | 0 | 98,340 | 79.3 K to 98.3 K (+23.95 %) |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 15.46 | 245 | 3,788 | 79,340 | 79.1 K to 79.3 K (+0.31 %) |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 20.52 | 4,688 | 96,198 | 79,095 | 74.4 K to 79.1 K (+6.30 %) |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 42.02 | 8,548 | 359,226 | 74,407 | 83 K to 74.4 K (-10.30 %) |
| Jun 25 2015 | STML | STEMLINE THERAPEUT ... | DOBMEIER ERIC | Director | Option Exercise | A | 12.76 | 24,000 | 306,240 | 24,000 | |
| Jun 25 2015 | STML | STEMLINE THERAPEUT ... | DOBMEIER ERIC | Director | Grant | A | 0.00 | 10,000 | 0 | 17,963 | 8 K to 18 K (+125.58 %) |
| May 08 2015 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 40.38 | 17,074 | 689,380 | 82,777 | 99.9 K to 82.8 K (-17.10 %) |
| Mar 30 2015 | ATRA | Atara Biotherapeut ... | DOBMEIER ERIC | Director | Option Exercise | A | 34.90 | 25,000 | 872,500 | 25,000 | |
| Aug 28 2014 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | M | 12.00 | 8,333 | 99,996 | 0 | |
| Aug 28 2014 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Buy | M | 12.00 | 8,333 | 99,996 | 99,765 | 91.4 K to 99.8 K (+9.11 %) |
| Aug 27 2014 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | A | 44.09 | 42,732 | 1,884,054 | 42,732 | |
| Aug 27 2014 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Option Exercise | A | 44.09 | 2,268 | 99,996 | 2,268 | |
| Aug 27 2014 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Grant | A | 0.00 | 18,000 | 0 | 91,432 | 73.4 K to 91.4 K (+24.51 %) |
| Aug 27 2014 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 43.55 | 4,818 | 209,819 | 73,432 | 78.3 K to 73.4 K (-6.16 %) |
| Jan 23 2014 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 48.02 | 14,959 | 718,271 | 77,833 | 92.8 K to 77.8 K (-16.12 %) |
| Jan 23 2014 | SGEN | SEATTLE GENETICS I ... | DOBMEIER ERIC | Chief Operating Off ... | Sell | S | 47.90 | 19,616 | 939,518 | 92,792 | 112.4 K to 92.8 K (-17.45 %) |